miR-675 expression correlates with age, menopausal status, tumor size, histology, clinical stages, ER status, HER2 status, non-TNBC, BRCA1 status, and BRCA2 status (P<0.05), but not with other clinical pathological parameters. Here, ERBB2 is linked to neoplasm.